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Background
In lesser-developed countries (LDCs), the causes of anaemia
during pregnancy are multi-factorial, yet much of the aetiological
fraction of disease is attributable to a few entities. Iron deficiency is
the most common cause of anaemia among pregnant women,
resulting from both dietary insufficiency of iron as well as losses
through the gastrointestinal tract. These losses are largely due to
hookworm infection, but schistosomiasis at higher intensities of
infection may also lead to blood loss [1].
The argument for hookworm treatment during pregnancy as
proposed by Brooker et al. [2] and the WHO [3] is based largely
on expected consequences of hookworm-related iron deficiency
anaemia for both mother and newborn. It is beyond the scope of
this commentary to address the complex relationship between
hemoglobin levels assessed at different stages of pregnancy and
peri-natal morbidity [4]. However, the relationship between iron
status early in pregnancy and birth outcomes is clearer and more
relevant here. It is fairly well established that iron deficiency
anaemia present during the first trimester of pregnancy is
associated with a 2-fold risk of low birth weight [5]. This risk is
much lower among women with non–iron deficiency anaemia
during the first trimester, arguing for an important mechanistic
role for iron per se, discussed in greater detail in recent reviews [6].
In addition to its effects on birth weight, transfer of iron to the
developing fetus is compromised among women with depleted iron
stores [7]. Maternal iron deficiency is related to decreased
newborn and infant iron stores, as well as increased risk of
anaemia during infancy [4]. Given the established relationship
between hookworm and iron deficiency, hookworm treatment is
likely to positively affect maternal and infant health, though the
timing of treatment as well as provision of micro-nutrient
supplementation are key factors discussed further below.
A Systematic Review of Hookworm-Related
Anaemia among Pregnant Women
Brooker and colleagues have conducted a timely and informative
meta-analysis examining the burden of hookworm among pregnant
women. In this meta-analysis, they have included cross-sectional,
observational, and randomized controlled trials to estimate the
contribution of hookworminfection to maternal anaemia. All studies
that provided quantitative data on both hookworm intensity of
infection and hemoglobin were included, yielding 19 for inclusion.
Overall, hookworm infection during pregnancy was related to a
standardized mean difference in hemoglobin of 20.24 g/dL in
comparinguninfected to lightlyinfected women, and20.57 g/dL in
comparing lightly infected to heavily infected women.
Strengths and Limitations of the Study
The limitations of this study are common to many meta-
analyses, whereby the quality of summary estimates are driven
largely by the quality of the studies included. This is particularly
challenging in the case of meta-analyses of cross-sectional and
observational studies where bias and confounding are more likely
to play a role than in well-executed randomized controlled trials
[8]. Approaches to this issue are to either judge the quality of
studies and then exclude based on a particular quality score, or
include all studies with careful consideration of the potential for
confounding or bias in interpretation of results. The latter
approach, taken by the authors, is potentially problematic in this
study given that a host of factors related to poverty may be related
to both hookworm and anaemia, thus confounding this relation-
ship. These potential confounders include an iron-deficient diet,
access to iron supplementation during pregnancy, schistosomiasis,
HIV, and malaria infections. If diseases of poverty related to both
hookworm infection and anemia are not adjusted for in analyses,
this variance may be wrongly attributed to hookworm, overesti-
mating its effect.
Though Brooker and colleagues did not exclude studies based
on quality, the summary of designs in Table 1 is fairly reassuring.
Many studies from malaria- and schistosomiasis-endemic regions
adjusted for these infections, and six of 13 studies adjusted for a
marker of poverty such as socio-economic status (SES) or maternal
education. An examination of Figure 1 suggests that studies which
did and did not adjust for SES seem to provide similar estimates of
hookworm effect, as also supported by results of heterogeneity
analyses. Though some residual confounding may have led to a
slight overestimate of effect, it is unlikely that this would change
the paper’s conclusions significantly.
Other limitations relate to use of observational studies to assess
changes in hemoglobin during pregnancy with treatment for
hookworm infection. This is limited by the expected hemodilution
that occurs in healthy pregnancies during the third trimester.
These studies likely underestimate the effect of treatment given
that most studies evaluated hemoglobin early in pregnancy and
then during the third trimester.
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The treatment trials discussed in this manuscript provide the
clearest insight into implications of this meta-analysis. It is beyond
the scope of this commentary to fully review those studies, but the
implications include the following:
1) The importance of concomitant administration of iron-folate
supplementation. Hookworm treatment alone may mitigate
ongoing losses during pregnancy but does nothing to
replenish depleted iron stores, which place mother and fetus
at risk. In a Peruvian study, the addition of mebendazole to
iron-folate provided no improvement in maternal hemoglo-
bin during the third trimester compared to iron-folate alone
[9]. A second study demonstrated a 0.66 g/dL difference in
albendazole-treated (early second trimester) versus untreated
women, with markedly increased impact with the addition of
iron-folate to 2.0 g/dL compared to control [10].
2) The health of women independent of their status during a
specific pregnancy is of paramount importance. Each cycle of
pregnancy and lactation is tremendously iron demanding,
with iron deficiency anaemia the third leading cause of
Disability Adjusted Life Years lost for females 15–44 years of
age [11]. It is clear that hookworm treatment plus iron
supplementation mitigates iron deficiency and leaves women
to face both future pregnancies and activities of daily living
healthier.
3) With respect to safety, findings are reassuring; however, the
safety analyses conducted using the Peruvian [12] and Sierra
Lione [10] data provided no estimates of power attained to
capture fairly rare outcomes such as stillbirths and malfor-
mations. A separate cross-sectional study conducted in Sri
Lanka had 80% power to detect an increased odds of 2.0 or
more for birth defects and found no increased risk with
mebendazole treatment during the second trimester [13].
Further, of noted birth defects among women who did or did
not receive mebendazole, there is no obvious pattern to
systems involved.
Next Steps
Much has been learned in the past two decades with respect to
the impact of specific diseases of LDCs and their impact on human
pregnancy. Next steps will require scientists with expertise in a
range of diseases to evaluate more complete and integrated
interventions to improve the health of both women of reproductive
age and their newborns. This includes the evaluation of optimal
timing of interventions. Although pregnancy remains a favorable
time to capture women of childbearing age, an approach whereby
women enter pregnancy in good health is ideal given the
minimization of risks of interventions to the fetus, the limited
period of recovery and benefit possible for interventions during
pregnancy, and the greater risk for interactions with interventions
that must be given during pregnancy such as therapeutics for
malaria and HIV. In addition, the examination of multiple
simultaneous interventions during pregnancy will be of increasing
importance as more drugs become available, most of which have
been examined in isolation. It is possible that drug combinations
confer a greater than additive risk of side effects. Further need to
simultaneously assess interventions is supported by a recent
example that raised the specter that iron supplementation during
pregnancy may increase malaria risk [14]. These concerns
notwithstanding, there is great potential to improve the health of
pregnant women in the coming decades if industrialized nations
provide much needed support, scientists from a range of
backgrounds collaborate to evaluate multiple concurrent inter-
ventions, and women’s socio-political status independent of their
role as mothers is improved.
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